OOIR: Observatory of International Research

Papers

(The median citation count of Best Practice & Research Clinical Endocrinology & Metabolism is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Myeloma and marrow adiposity: Unanswered questions and future directions	102
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	101
Editorial Board	68
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	65
Editorial Board	52
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	52
Editorial Board	51
Menopausal hormone therapy for the management of osteoporosis	50
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	47
Genetics of pubertal timing	43
Regulation of bone mass: A splendid Orchestra	42
Coronavirus disease 2019 and vitamin D	40
Editorial Board	38
The role of androgens in transgender medicine	37
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	37
Rare forms of genetic steroidogenic defects affecting the gonads and adrenals	37
Sexual health and contraception in the menopause journey	36
Prenatal exposure to phthalate esters and its impact on child development	35
Editorial Board	34
Immune checkpoint inhibitor-related thyroid dysfunction	34
Remnant lipoprotein particles and cardiovascular disease risk	33
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	32
Cardiometabolic outcomes of early onset hypogonadism in males	31
Haematological actions of androgens	28
Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	27

Type 1 diabetes related to immune checkpoint inhibitors	27
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	26
Bone marrow adiposity and the hematopoietic niche: A historical perspective of reciprocity, heterogeneity, and lineage commitment	26
Endocrine-disrupting chemicals and behaviour: A high risk to take?	26
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	24
Metabolic complications and their mechanisms in patients with craniopharyngioma	24
Medullary thyroid cancer - An update	24
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	24
Radioiodine therapy in the different stages of differentiated thyroid cancer	24
Non-oestrogen-based and complementary therapies for menopause	23
The effect of osteoporosis treatment on bone mass	22
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	22
Approach to patients with elevated low-density lipoprotein cholesterol levels	21
Hormone therapy for menopause and premature ovarian insufficiency	21
Pathophysiology of thyroid-associated orbitopathy	21
Immune checkpoint inhibitor-related hypophysitis	21
Onco-immuno-endocrinology: An emerging concept that links tumor, autoimmunity, and endocrine disease	21
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	20
Editorial Board	20
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	20
Safety of androgen therapy in men with prostate cancer	20
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	20
History of androgens and androgen action	19
Localization in primary hyperparathyroidism	19
The role of hormone therapy in urogenital health after menopause	19
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	19
Genetics of anti-Müllerian hormone and its signaling pathway	18
Editorial Board	18
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	18
Editorial Board	18
Genotype-phenotype correlations in Graves’ disease	18
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	18
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	17
Endocrine disrupting chemicals and bone	17
Preface	17
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	17
Anaplastic thyroid cancer: An update	16
COVID-induced thyroid autoimmunity	16
Chemokines in thyroid autoimmunity	16
Exercise and physical activity in individuals at risk of fracture	16
Preface	15
Paraneoplastic autoimmune hypophysitis: An emerging concept	15
The epidemiology of disorders of sex development	15
Editorial Board	15
Preclinical models for investigating how bone marrow adipocytes influence bone and hematopoietic cellularity	15
Genetic variants of gonadotrophins and their receptors: Impact on the diagnosis and management of the infertile patient	14
Surgical treatment of thyroid cancer: Established and novel approaches	14
Covid-19 and endocrinology	14
How best to monitor the specific side effects of medical treatments of Cushing’s disease	14
The interplay between thyrotropic axis, neurological complications, and rehabilitation outcomes in patients with traumatic brain injury	14

Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess	14
Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists	14
Endocrine abnormality in paraneoplastic syndrome	13
Editorial Board	13
Role of sex steroids hormones in the regulation of bone metabolism in men: Evidence from clinical studies	13
Exposure to endocrine-disrupting compounds such as phthalates and bisphenol A is associated with an increased risk for obesity	13
Menopausal hormone therapy in women with medical conditions	12
Quality of life in thyroid cancer	12
The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I	12
SARS-CoV-2 infection and its effects on the endocrine system	12
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors	11
Adolescent primary hyperparathyroidism	11
Management of patients with statin intolerance	11
Genetics of 46,XY gonadal dysgenesis	10
Androgen-based therapies in women	10
Long-term thionamide antithyroid treatment of Graves' disease	10
Regulation of bone mass in endocrine diseases including diabetes	10
Real-world value of cabergoline in the treatment of acromegaly	10
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism	9
Current medical treatment and perspective in gonadotroph tumors	9
Newly detected diabetes during the COVID-19 pandemic: What have we learnt?	9
Editorial Board	9
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?	9
COVID-19 vaccination and thyroiditis	9
Publisher's Note	9
Burosumab: Current status and future prospects	8
Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors	8
Vitamin D deficiency or resistance and hypophosphatemia	8
Editorial Board	8
Neural regulation of bone marrow adipose tissue	8
Androgens part 2: Emerging areas	8
Novel androgen therapies including selective androgen receptor modulators	8
Pituitary and SARS CoV-2: An unremitting conundrum	8
Pre-clinical phaeochromocytoma and paraganglioma models: Cell lines, animal models, and a human primary culture model	7
Tumor-induced osteomalacia: An overview	7
Mild traumatic brain injury as a cause of adult growth hormone deficiency: Diagnosis and treatment	7
Phthalates, ovarian function and fertility in adulthood	7
Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model	7
Associations of prenatal exposure to phthalates and one phthalate substitute with anthropometric measures in early life: Results from the German LIFE Child cohort study	7
Heritable hyperparathyroidism: Genetic insights and clinical implications	7
Inherited fibroblast growth factor 23 excess	7
Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders	6
Androgen therapy for women after menopause	6
Morbidity and mortality in men: Role of androgens	6
New advances in menopause symptom management	5
Innovative therapeutics in acromegaly	5
Marrow adipogenic lineage precursor: A new cellular component of marrow adipose tissue	5
Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know	5
Pituitary neuroendocrine tumors: from old treatments to innovations, from efficacy to tolerance, from benignity to carcinomas, where do we stand now?	5
Traumatic brain injury, abnormal growth hormone secretion, and gut dysbiosis	5
Management of non-hepatic distant metastases in neuroendocrine neoplasms	5
Genetics of ovarian insufficiency and defects of folliculogenesis	5
Pituitary dysfunction due to sports injuries	5
Bone marrow adipose tissue: Role in bone remodeling and energy metabolism	5
Primary hyperparathyroidism	4
Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective	4
Clinical imaging of marrow adiposity	4
Perinatal exposure to endocrine disrupting chemicals and neurodevelopment: How articles of daily use influence the development of our children	4
Second line treatment of acromegaly: Pasireotide or Pegvisomant?	4
Androgens, sports, and detection strategies for anabolic drug use	4
In utero exposure to phthalates and reproductive toxicity in rodents	4
Editorial Board	4
The pathophysiology of hypophosphatemia	4
Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review	4
Thyroid hormone system disrupting chemicals	4
Editorial Board	4
SDH-related head and neck paragangliomas: Unraveling PET radiomics beyond 18F-FDG	4